BASEL, Switzerland — October 1, 2026
Roche announced new real-world data from the VOYAGER study evaluating Vabysmo® (faricimab) in people with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). The study, which includes more than 5,000 patients across 28 countries and regions, showed vision gains and anatomical improvements in previously untreated eyes, while previously treated eyes generally maintained or improved vision with reductions in central subfield thickness. No new safety signals were identified.
Vabysmo Shows Vision and Anatomical Improvements Across Retinal Diseases
VOYAGER results demonstrated improvements in visual acuity and retinal anatomy across the evaluated conditions. In nAMD, previously untreated eyes gained an average of 4.6 ETDRS letters and experienced a 110.5 µm reduction in central subfield thickness after 12 months, while previously treated eyes maintained vision with a 26.1 µm reduction in thickness. In DME, previously untreated eyes gained 8.2 letters with a 127.8 µm reduction in thickness, while previously treated eyes gained 2.7 letters with a 71.3 µm reduction. In RVO, both central/hemi-RVO and branch RVO cohorts demonstrated improvements in visual acuity and central subfield thickness, particularly among previously untreated eyes.
VOYAGER Shows Reduction in Retinal Fluid and Treatment Durability
The study also demonstrated reductions in subretinal fluid (SRF) and intraretinal fluid (IRF) across the major retinal disease cohorts. In nAMD, SRF presence declined from 72.1% to 25.3% in previously untreated eyes, while IRF declined from 48.5% to 20.6%. In DME, SRF decreased from 26.5% to 6.8% and IRF from 87.3% to 58.1% among previously untreated eyes. The RVO cohorts similarly showed reductions in retinal fluid after six months of Vabysmo treatment. In nAMD and DME, fewer injections were administered during months 7–12 compared with months 1–6, suggesting that treatment intervals could be extended for some patients.
Advertisement
AI-Enabled Imaging Supports Real-World Vabysmo Assessment
VOYAGER incorporates AI and deep-learning technologies to analyze SD-OCT imaging collected during routine clinical practice. The advanced imaging analysis provides quantitative assessments of retinal anatomy and fluid changes across diverse patient populations and treatment histories. Roche said the findings are consistent with previous Phase III results and support the effectiveness, durability and established safety profile of Vabysmo in routine clinical settings. Vabysmo is a bispecific antibody targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) and is approved in multiple countries for several vision-threatening retinal conditions.
Source: Roche press release
